Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape
Disease and Disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).
Browse more detail information about Gastrointestinal Drug Market to 2022 Report at:
Despite the significant global socio-economic burden, many gastrointestinal disorders are still poorly understood, and there is a significant unmet need for novel, safe and effective therapies, as treatment options are often lacking, causing many patients to be dissatisfied with their treatment. The unmet need and demand for better treatments and the high prevalence of digestive conditions make the gastrointestinal market an attractive candidate for therapeutic development.
This Report Covers all gastrointestinal disorders, but there is a particular focus on three key diseases: gastroesophageal reflux disease, irritable bowel syndrome and inflammatory bowel disease. The global gastrointestinal market was valued at $35.7 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.45%, reaching $48.4 billion in 2022. Proton pump inhibitors (PPIs) and tumor necrosis factor (TNF)-α inhibitors generate the largest revenues and continue to retain commercial prominence.
Get a PDF Sample of Gastrointestinal Drug Market Research Report at:
Scope of Gastrointestinal Drug Market to 2022:
The gastrointestinal market landscape is expected to change substantially with the advent of promising novel pipeline products.
There are 937 gastrointestinal pipeline products in active development, of which small molecules and biologics account for 53% and 38%, respectively.
Purchase Report @ http://www.absolutereports.com/purchase/10399931
Reasons to buy Gastrointestinal Drug Market to 2022:
This report will allow you to –
Have any query? Ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10399931
Detailed TOC of Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape
Get Discount on Gastrointestinal Drug Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10399931
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.